This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.
Evercore ISI Sticks to Their Hold Rating for Eli Lilly & Co (LLY)
Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares closed ...
My Top 5 Stocks to Buy in Early 2025
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
Human Growth Hormone Powder Injection Market Growth Anticipated At 19.34% CAGR, Reaching 13.75 Billion USD
The global Human Growth Hormone Powder Injection market is poised for immense growth, propelled by a surge in chronic diseases and the increasing prevalence ...
Hosted on MSN14h
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
In the latest trading session, Eli Lilly (LLY) closed at $753.98, marking a +1.57% move from the previous day. This move outpaced the S&P 500's daily gain of 0.61%. Meanwhile, the Dow gained 0.3%, and ...
Top SA Quant-rated medical devices stocks as technicals look strong
Medical devices stocks are in a strong position “and must be bought,” according to Rich Ross, head of Technical Analysis at Evercore ISI, in a note. The iShares U.S. Medical Device ETF (NYSEARCA:IHI) ...
Pliant Therapeutics, Inc.: Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer
Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...